VEGFA and non-small cell lung carcinoma: In 2003, the FDA approved Bevacizumab, a humanized VEGF neutralizing monoclonal antibody, as the first anti-angiogenic agent for combinatorial treatment of metastatic CRC and subsequently for treating patients with non-small-cell lung cancer (NSCLC) (92, 93).